© 2024 BioNTech SE. All Rights Reserved
Now Enrolling:
Immuno-oncology clinical study for patients
with head and neck squamous cell carcinoma (HNSCC HPV16+/PD-L1+)
with head and neck squamous cell carcinoma (HNSCC HPV16+/PD-L1+)
The AHEAD-MERIT study is evaluating BNT113, an RNA-based investigational therapeutic cancer vaccine, for patients with HNSCC that are positive for human papilloma virus 16 (HPV16+) and programmed death ligand 1 (PD-L1).
BNT113:
●
Is designed to be a ribonucleic acid-lipoplex (RNA-LPX) vaccine
●
Is intended to target HPV16 oncoproteins E6 and E7
●
Will be administered in combination with pembrolizumab versus pembrolizumab monotherapy in the AHEAD-MERIT study
Download the
Patient Brochure
Download
Who can participate in this study?
Patients who meet the following criteria may qualify.
●
18 years+ with unresectable recurrent or metastatic HPV16+ HNSCC
●
Have histologically confirmed recurrent or metastatic HPV16+ HNSCC that is considered incurable by local therapies
●
Have a tumor located in the oropharynx, oral cavity, hypopharynx, and/or larynx that expresses programmed death ligand 1 (PD-L1)
This is not a full list of criteria. Please refer to Clinicaltrials.gov (NCT04534205) for more eligibility requirements.
Study Summary
Study Treatment:
1:1 randomization with pembrolizumab or pembrolizumab +BNT113
Participant Details:
18 years+ with unresectable
recurrent or metastatic
HPV16+ HNSCC
recurrent or metastatic
HPV16+ HNSCC
Sponsor
BioNTech
Trial Status:
Currently Enrolling
Study Site Locations
Click on the map below to see study site locations near you.
Location
Click to copy and paste nearby study site locations into your patient notes.
